Histone deacetylase inhibitors in the treatment for multiple myeloma : PIH: Basic and Clinical Updates in Multiple MyelomaHIDESHIMA, Teru; ANDERSON, Kenneth C.International journal of hematology. 2013, Vol 97, Num 3, pp 324-332, issn 0925-5710, 9 p.Article

Novel therapies in MM: from the aspect of preclinical studies : PIH: Understanding the Pathogenesis and the Evolving Treatment Paradigm for Multiple Myeloma in the Era of Novel AgentsHIDESHIMA, Teru; ANDERSON, Kenneth C.International journal of hematology. 2011, Vol 94, Num 4, pp 344-354, issn 0925-5710, 11 p.Article

Apoptotic signaling in multiple myeloma: Therapeutic implicationsCHAUHAN, Dharminder; HIDESHIMA, Teru; ANDERSON, Kenneth C et al.International journal of hematology. 2003, Vol 78, Num 2, pp 114-120, issn 0925-5710, 7 p.Article

Preclinical Studies of Novel Targeted TherapiesHIDESHIMA, Teru; ANDERSON, Kenneth C.Hematology/oncology clinics of North America. 2007, Vol 21, Num 6, issn 0889-8588, viii-ix, 1071-1091 [22 p.]Article

Therapeutic use of immunomodulatory drugs in the treatment of multiple myelomaRAJE, Noopur; HIDESHIMA, Teru; ANDERSON, Kenneth C et al.Expert review of anticancer therapy. 2006, Vol 6, Num 9, pp 1239-1247, issn 1473-7140, 9 p.Article

Proteasome inhibition in multiple myeloma: Therapeutic implicationCHAUHAN, Dharminder; HIDESHIMA, Teru; ANDERSON, Kenneth C et al.Annual review of pharmacology and toxicology. 2005, Vol 45, pp 465-476, issn 0362-1642, 12 p.Article

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myelomaYASUI, Hiroshi; HIDESHIMA, Teru; RICHARDSON, Paul G et al.British journal of haematology. 2006, Vol 132, Num 4, pp 385-397, issn 0007-1048, 13 p.Article

Proteasome inhibition in hematologic malignancies : Proteasome inhibitionRICHARDSON, Paul G; HIDESHIMA, Teru; MITSIADES, Constantine et al.Annals of medicine (Helsinki). 2004, Vol 36, Num 4, pp 304-314, issn 0785-3890, 11 p.Article

Intracellular protein degradation and its therapeutic implicationsHIDESHIMA, Teru; BRADNER, James E; CHAUHAN, Dharminder et al.Clinical cancer research. 2005, Vol 11, Num 24, pp 8530-8533, issn 1078-0432, 4 p., 1Article

Novel therapeutic approaches for multiple myelomaHIDESHIMA, Teru; RICHARDSON, Paul; ANDERSON, Kenneth C et al.Immunological reviews. 2003, Vol 194, pp 164-176, issn 0105-2896, 13 p.Article

Advances in biology of multiple myeloma: clinical applicationsHIDESHIMA, Teru; BERGSAGEL, P. Leif; KUEHL, W. Michael et al.Blood. 2004, Vol 104, Num 3, pp 607-618, issn 0006-4971, 12 p.Article

Proteasome inhibition as a novel therapeutic target in human cancerRAJKUMAR, S. Vincent; RICHARDSON, Paul G; HIDESHIMA, Teru et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 630-639, issn 0732-183X, 10 p.Article

Proteasome inhibition as a therapeutic strategy for hematoloqic maliqnanciesMITSIADES, Constantine S; MITSIADES, Nicholas; HIDESHIMA, Teru et al.Expert review of anticancer therapy. 2005, Vol 5, Num 3, pp 465-476, issn 1473-7140, 12 p.Article

Biologic sequelae of c-Jun NH₂-terminal kinase (JNK) activation in multiple myeloma cell linesHIDESHIMA, Teru; HAYASHI, Toshiaki; CHAUHAN, Dharminder et al.Oncogene (Basingstoke). 2003, Vol 22, Num 54, pp 8797-8801, issn 0950-9232, 5 p.Article

Targeting the phosphatidylinositol 3-kinase pathway in multiple myelomaYOUNES, Hashem; LELEU, Xavier; HATJIHARISSI, Evdoxia et al.Clinical cancer research. 2007, Vol 13, Num 13, pp 3771-3775, issn 1078-0432, 5 p.Article

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsHIDESHIMA, Teru; RICHARDSON, Paul; CHAUHAN, Dharminder et al.Cancer research (Baltimore). 2001, Vol 61, Num 7, pp 3071-3076, issn 0008-5472Article

New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase InhibitorsCEA, Michele; CAGNETTA, Antonia; GOBBI, Marco et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 4, pp 734-744, issn 1381-6128, 11 p.Article

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaCHAUHAN, Dharminder; SINGH, Ajita; BRAHMANDAM, Mohan et al.Blood. 2008, Vol 111, Num 3, pp 1654-1664, issn 0006-4971, 11 p.Article

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applicationsMITSIADES, Constantine S; TREON, Steven P; MITSIADES, Nicholas et al.Blood. 2001, Vol 98, Num 3, pp 795-804, issn 0006-4971Article

Novel therapies targeting the myeloma cell and its bone marrow microenvironmentHIDESHIMA, Teru; CHAUHAN, Dharminder; PODAR, Klaus et al.Seminars in oncology. 2001, Vol 28, Num 6, pp 607-612, issn 0093-7754Article

Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple MyelomaFABRE, Claire; MIMURA, Naoya; MESHULAM, Jeffrey et al.Clinical cancer research (Print). 2012, Vol 18, Num 17, pp 4669-4681, issn 1078-0432, 13 p.Article

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agentsLEIBA, Merav; JAKUBIKOVA, Jana; ANDERSON, Kenneth C et al.British journal of haematology. 2012, Vol 157, Num 6, pp 718-731, issn 0007-1048, 14 p.Article

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with LenalidomideSANTO, Loredana; HIDESHIMA, Teru; UNITT, Christine et al.Clinical cancer research (Print). 2011, Vol 17, Num 10, pp 3259-3271, issn 1078-0432, 13 p.Article

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGÖRGÜN, Güllü; CALABRESE, Elisabetta; SANTO, Loredana et al.Blood. 2010, Vol 115, Num 25, pp 5202-5213, issn 0006-4971, 12 p.Article

Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implicationsHIDESHIMA, Teru; CHAUHAN, Dharminder; CARRASCO, Ruben D et al.Blood. 2009, Vol 113, Num 21, pp 5228-5236, issn 0006-4971, 9 p.Article